1Olivieri A,,Manzione L.Dasatinib:a newstepin molecular tar-get therapy[].Annals of Oncology.2007
2Dai G,Pfister M,Blackwood Chirchir A,et al.I mportance ofcharacterizing det-erminants of variabilityin exposure:applica-tion to dasatinibin subjects with chronic myeloidleukemia[].Journal of Clinical Pharmacology.2008
3Wappl M,Jaeger E,Streubel B,et al.Dasatinibinhibits progen-itor cell prolifer-ation from polycythaemia vera[].European Journal of Clinical Investigation.2008
4Guilhot F,Apperley J,Ki m D W,et al.Dasatinib induces sig-nificant hematologic and cytogenetic responsesin patients withi matinib-resistant or-intolerant chronic myeloidleukemiain ac-celerated phase[].Blood.2007
5Soverini S,Martinelli G,Colarossi S,et al.Presence or the e-mergence of a F317LBCR-ABL mutation may be associatedwith resistance to dasatinib in Philadelphia chromosome-posi-tive leukemia[].Journal of Clinical Oncology.2006
6Fraser C K,Lousberg E L,Kumar R,et al.Dasatinib inhibitsthe secretion of TNF-alpha following TLRsti mulationin vitroandin vivo[].Experimental Hematology.2009
7Shah NP,Lee FY,Luo R,et al.Dasatinib(BMS-354825)in-hibits KITD816V,an imatinib resistant activating mutationthat triggers neoplastic growth in most patients with systemicmastocytosis[].Blood.2006
8J Cortes,P Rousselot,DW Kim.Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis[].Blood.2007
9MM Schittenhelm,S Shiraga,A Schroeder,AS Corbin,D Griffith,FY Lee.Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies[].Cancer Research.2006
10Steinberg M.Dasatinib:A Tyrosine kinase inhibitor for the treatment of chronic Myelogenous Leukemia and Philadel-phia Chromosome-Positive Acute Lymphoblastic Leukemia[].Clinical Therapeutics.2007
3Aguilera DG, Tsimberidou AM, Dasainib in chronic myeloid leukemia: a review[J]. Ther Clin Risk Manag, 2009,5(6): 281-289.
4Kantarjian H, Shah NP, Hochaus A, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European leukemianet[J]. N Engl J Med, 2010, 362(6): 2260-2270.
5Kim D, Goh YT, Hsiao HH, et al. Clinical profile of daseatinib in Asian and non Asian patients with chronic myeloid leukemia[J], Int J Hematol, 2009, 89(5): 664-672.
